Table 1.
Baseline Demographic & Clinical Characteristics (n=122 European-Americans)
| A-Allele Carriers | C-Allele Homozygotes | |||
|---|---|---|---|---|
| Topiramate (n=35) | Placebo (n=36) | Topiramate (n=21) | Placebo (n=30) | |
|
| ||||
| Demographic Features | ||||
| Sex (Male) | 62.9% | 66.7% | 71.4% | 46.7% |
| Agea | 50.1 ± 6.7 | 53.6 ± 8.0 | 51.7 ± 8.3 | 52.5 ± 6.4 |
| Married | 65.7% | 66.7% | 66.7% | 66.7% |
| Years of Educationa | 15.6 ± 2.1 | 15.3 ± 2.6 | 15.7 ± 2.4 | 15.0 ± 2.2 |
| Clinical Features | ||||
| 90-Day TLFB | ||||
| PHDD | 67.2 ± 28.8 | 61.1 ± 25.1 | 70.4 ± 25.0 | 72.5 ± 27.4 |
| Percent Days Abstinent* | 10.8 ± 15.1 | 14.4 ± 15.4 | 12.1 ± 14.7 | 6.8 ± 11.5 |
| SIP score | 15.2 ± 9.1 | 15.0 ± 6.8 | 14.5 ± 8.0 | 15.4 ± 6.5 |
| BDI score | 5.1 ± 3.7 | 6.8 ± 5.2 | 7.4 ± 5.1 | 6.8 ± 5.1 |
a
Mean (SD). BDI=Beck Depression Inventory: SIP=Short Index of Problems; TLFB= Timeline Follow-back Interview; PHDD=Percent Heavy Drinking Days
*
p=0.093 for genotype by medication interaction